^
No biomarker
Triple Negative Breast Cancer
sacituzumab govitecan-hziy
Sensitive: A1 - Approval
Gilead Press Release - 4 days
HER-2 positive
HER2 Positive Breast Cancer
lapatinib
Sensitive: A2 - Guideline
Nature - 4 days
HER-2 amplification + HER-2 L755S
HER2 Positive Breast Cancer
pyrotinib
Sensitive: C4 – Case Studies
Front Oncol - 5 days
HR positive
HER2 Negative Breast Cancer
exemestane
Sensitive: A2 - Guideline
SABCS 2021 - 1 week
ESR1 mutation + HR positive
HER2 Negative Breast Cancer
palbociclib
Sensitive: B - Late Trials
SABCS 2021 - 1 week
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + tucatinib
Sensitive: A1 - Approval
SABCS 2021 - 1 week
HER-2 positive
HER2 Positive Breast Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
SABCS 2021 - 1 week
HR positive
HER2 Negative Breast Cancer
palbociclib
Sensitive: A1 - Approval
JAMA Oncol - 1 week
HR positive
HER2 Negative Breast Cancer
abemaciclib
Sensitive: A1 - Approval
FDA - 1 week
HER-2 positive
HER2 Positive Breast Cancer
pyrotinib
Sensitive: B - Late Trials
SABCS 2021 - 1 week
HR positive
HER2 Negative Breast Cancer
ribociclib + letrozole
Sensitive: B - Late Trials
SABCS 2021 - 1 week
HER-2 overexpression
HER2 Positive Breast Cancer
trastuzumab + MCLA-128
Sensitive: C3 – Early Trials
SABCS 2021 - 1 week
ASXL1 mutation
Estrogen Receptor Positive Breast Cancer
CDK6 inhibitor
Sensitive: C3 – Early Trials
SABCS 2021 - 1 week
ASXL1 mutation
Estrogen Receptor Positive Breast Cancer
CDK4 inhibitor
Sensitive: C3 – Early Trials
SABCS 2021 - 1 week
HR positive
HER2 Negative Breast Cancer
EC
Sensitive: C4 – Case Studies
Front Endocrinol (Lausanne) - 1 week
PIK3CA H1047R + PIK3CA D959N + ER E380Q
HER2 Negative Breast Cancer
abemaciclib
Resistant: C4 – Case Studies
Front Endocrinol (Lausanne) - 1 week
HER-2 positive
HER2 Positive Breast Cancer
HER2 inhibitor
Sensitive: A2 - Guideline
Breast - 2 weeks
IGFBP7 overexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive: B - Late Trials
Carcinogenesis - 2 weeks
HR negative
HER2 Negative Breast Cancer
AMG479
Sensitive: C3 – Early Trials
Nature - 2 weeks
IGFBP5-L
HER2 Negative Breast Cancer
AMG479
Sensitive: C3 – Early Trials
Nature - 2 weeks
IRS1-L
HER2 Negative Breast Cancer
AMG479
Sensitive: C3 – Early Trials
Nature - 2 weeks
FGFR4 overexpression
Breast Cancer
FGFR inhibitor
Sensitive: D – Preclinical
Clin Cancer Res - 2 weeks
FGFR3 overexpression
Breast Cancer
FGFR inhibitor
Sensitive: D – Preclinical
Clin Cancer Res - 2 weeks
FGFR2 overexpression
Breast Cancer
FGFR inhibitor
Sensitive: D – Preclinical
Clin Cancer Res - 2 weeks
FGFR1 overexpression
Breast Cancer
FGFR inhibitor
Sensitive: D – Preclinical
Clin Cancer Res - 2 weeks
HER-2 positive
HER2 Positive Breast Cancer
ado-trastuzumab emtansine
Sensitive: A1 - Approval
Cancer - 2 weeks
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab
Sensitive: A1 - Approval
Mol Oncol - 3 weeks
HER-2 positive
HER2 Positive Breast Cancer
neratinib
Sensitive: A1 - Approval
Oncogene - 3 weeks
MSI-H/dMMR
Breast Cancer
pembrolizumab
Sensitive: A2 - Guideline
Clin Nucl Med - 3 weeks
HR positive
HER2 Negative Breast Cancer
eribulin mesylate
Sensitive: C2 – Inclusion Criteria
SAGE Journals - 3 weeks
HER-2 overexpression
HER2 Positive Breast Cancer
ado-trastuzumab emtansine
Sensitive: C2 – Inclusion Criteria
Cancer - 2 weeks
CXXC5 overexpression
HER2 Positive Breast Cancer
ado-trastuzumab emtansine
Resistant: C3 – Early Trials
Cancer - 2 weeks
PGR overexpression
HER2 Positive Breast Cancer
ado-trastuzumab emtansine
Resistant: C3 – Early Trials
Cancer - 2 weeks
GRB7 overexpression
HER2 Positive Breast Cancer
ado-trastuzumab emtansine
Sensitive: C3 – Early Trials
Cancer - 2 weeks
BAG1 overexpression
HER2 Positive Breast Cancer
ado-trastuzumab emtansine
Sensitive: C3 – Early Trials
Cancer - 2 weeks
RRM2 overexpression
HER2 Positive Breast Cancer
ado-trastuzumab emtansine
Sensitive: C3 – Early Trials
Cancer - 2 weeks
ER overexpression
HER2 Positive Breast Cancer
ado-trastuzumab emtansine
Resistant: C3 – Early Trials
Cancer - 2 weeks
SLC39A6 overexpression
HER2 Positive Breast Cancer
ado-trastuzumab emtansine
Resistant: C3 – Early Trials
Cancer - 2 weeks
TMEM45B overexpression
HER2 Positive Breast Cancer
ado-trastuzumab emtansine
Sensitive: C3 – Early Trials
Cancer - 2 weeks
MAPT overexpression
HER2 Positive Breast Cancer
ado-trastuzumab emtansine
Resistant: C3 – Early Trials
Cancer - 2 weeks
FBXL20 overexpression
Breast Cancer
SA033
Resistant: D – Preclinical
J Biol Chem - 3 weeks
MUC1 expression
HER2 Positive Breast Cancer
MUC1 inhibitor
Sensitive: D – Preclinical
Acta Biochim Biophys Sin (Shanghai) - 2 weeks
FGFR2 amplification
Breast Cancer
TAS 120
Sensitive: C2 – Inclusion Criteria
Cancer Discov - 3 weeks
PD-L1 expression
Triple Negative Breast Cancer
atezolizumab
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + pertuzumab
Sensitive: A1 - Approval
HER-2 amplification
Breast Cancer
neratinib
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
margetuximab
Sensitive: A1 - Approval
No biomarker
Breast Cancer
docetaxel + doxorubicin hydrochloride + cyclophosphamide oral
Sensitive: A1 - Approval
No biomarker
Breast Cancer
TAC
Sensitive: A1 - Approval
HR positive
HER2 Positive Breast Cancer
neratinib
Sensitive: A1 - Approval
HR positive
HER2 Negative Breast Cancer
ribociclib
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
pertuzumab/trastuzumab/hyaluronidase-zzxf
Sensitive: A1 - Approval
PIK3CA mutation + HR positive
HER2 Negative Breast Cancer
alpelisib
Sensitive: A1 - Approval
PD-L1 expression
Triple Negative Breast Cancer
pembrolizumab
Sensitive: A1 - Approval
HER-2 amplification
Hormone Receptor Positive Breast Cancer
Trazimera (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
Trazimera (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
HER2 Positive Breast Cancer
Trazimera (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
HER2 Positive Breast Cancer
Trazimera (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
Hormone Receptor Positive Breast Cancer
Ontruzant (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
Ontruzant (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
HER2 Positive Breast Cancer
Ontruzant (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
HER2 Positive Breast Cancer
Ontruzant (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
Hormone Receptor Positive Breast Cancer
Ogivri (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
Ogivri (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
HER2 Positive Breast Cancer
Ogivri (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
HER2 Positive Breast Cancer
Ogivri (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
Hormone Receptor Positive Breast Cancer
Kanjinti (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
Kanjinti (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
HER2 Positive Breast Cancer
Kanjinti (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
HER2 Positive Breast Cancer
Kanjinti (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
Hormone Receptor Positive Breast Cancer
Herzuma (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
HER2 Positive Breast Cancer
Herzuma (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
Herzuma (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
HER2 Positive Breast Cancer
Herzuma (trastuzumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Breast Cancer
Mvasi (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Breast Cancer
pegylated liposomal doxorubicin
Sensitive: A1 - Approval
No biomarker
Breast Cancer
Zirabev (bevacizumab biosimilar)
Sensitive: A1 - Approval
HR positive
Hormone Receptor Positive Breast Cancer
ribociclib
Sensitive: A1 - Approval
ER negative
Breast Cancer
toremifene
Resistant: A1 - Approval
No biomarker
Breast Cancer
toremifene
Sensitive: A1 - Approval
No biomarker
Breast Cancer
albumin-bound paclitaxel
Sensitive: A1 - Approval
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
lapatinib
Sensitive: A1 - Approval
HER-2 overexpression
Hormone Receptor Negative Breast Cancer
trastuzumab + lapatinib
Sensitive: A1 - Approval
HER-2 overexpression
Breast Cancer
lapatinib
Sensitive: A1 - Approval
HR positive
HER2 Negative Breast Cancer
everolimus
Sensitive: A1 - Approval
BRCA2 mutation
HER2 Negative Breast Cancer
talazoparib
Sensitive: A1 - Approval
BRCA1 mutation
HER2 Negative Breast Cancer
talazoparib
Sensitive: A1 - Approval
No biomarker
Breast Cancer
docetaxel + doxorubicin hydrochloride
Sensitive: A1 - Approval
HER-2 overexpression
Breast Cancer
trastuzumab
Sensitive: A1 - Approval
No biomarker
Breast Cancer
docetaxel
Sensitive: A1 - Approval
No biomarker
Breast Cancer
docetaxel + capecitabine
Sensitive: A1 - Approval
No biomarker
Breast Cancer
capecitabine
Sensitive: A1 - Approval
HR positive
HER2 Positive Breast Cancer
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
ER positive
Estrogen Receptor Positive Breast Cancer
fulvestrant
Sensitive: A1 - Approval
No biomarker
Breast Cancer
eribulin mesylate
Sensitive: A1 - Approval
No biomarker
Breast Cancer
non-pegylated liposomal doxorubicin
Sensitive: A1 - Approval
HER-2 overexpression
Breast Cancer
trastuzumab/hyaluronidase-oysk
Sensitive: A1 - Approval
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
neratinib
Sensitive: A1 - Approval
HR positive
Hormone Receptor Positive Breast Cancer
olaparib
Sensitive: A1 - Approval
HER-2 overexpression
Breast Cancer
Ontruzant (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Breast Cancer
Trazimera (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Breast Cancer
Herzuma (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Breast Cancer
Kanjinti (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 overexpression
Breast Cancer
Ogivri (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
Hormone Receptor Positive Breast Cancer
neratinib
Sensitive: A1 - Approval
HER-2 overexpression
HER2 Positive Breast Cancer
trastuzumab
Sensitive: A1 - Approval
No biomarker
Breast Cancer
bevacizumab
Sensitive: A1 - Approval
HER-2 overexpression
Breast Cancer
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
ER positive
Estrogen Receptor Positive Breast Cancer
exemestane
Sensitive: A1 - Approval
No biomarker
Breast Cancer
exemestane
Sensitive: A1 - Approval
No biomarker
Breast Cancer
letrozole
Sensitive: A1 - Approval
HR positive
Hormone Receptor Positive Breast Cancer
letrozole
Sensitive: A1 - Approval
HR positive
Hormone Receptor Positive Breast Cancer
anastrozole
Sensitive: A1 - Approval
No biomarker
Breast Cancer
anastrozole
Sensitive: A1 - Approval
ER negative
Breast Cancer
anastrozole
Sensitive: A1 - Approval
ER positive
Estrogen Receptor Positive Breast Cancer
toremifene
Sensitive: A1 - Approval
HER-2 amplification
Breast Cancer
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Breast Cancer
ixabepilone
Sensitive: A1 - Approval
BRCA1 mutation
HER2 Negative Breast Cancer
olaparib
Sensitive: A1 - Approval
BRCA2 mutation
HER2 Negative Breast Cancer
olaparib
Sensitive: A1 - Approval
HER-2 overexpression
Breast Cancer
neratinib
Sensitive: A1 - Approval
No biomarker
Breast Cancer
Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
HR positive
Hormone Receptor Positive Breast Cancer
talazoparib
Sensitive: A1 - Approval
HR positive
Hormone Receptor Positive Breast Cancer
fulvestrant
Sensitive: A1 - Approval
HR positive
HER2 Negative Breast Cancer
fulvestrant
Sensitive: A1 - Approval
No biomarker
Triple Negative Breast Cancer
pembrolizumab
Sensitive: A1 - Approval
No biomarker
Breast Cancer
leuprorelin depot
Sensitive: A1 - Approval
HER-2 overexpression
Breast Cancer
trastuzumab + docetaxel
Sensitive: A1 - Approval
No biomarker
Breast Cancer
Bevax (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Breast Cancer
Krabeva (bevacizumab biosimilar)
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
TCHP
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
CaT
Sensitive: A2 - Guideline
ER positive
HER2 Positive Breast Cancer
trastuzumab + lapatinib
Sensitive: A2 - Guideline
NTRK2 fusion
Breast Cancer
entrectinib
Sensitive: A2 - Guideline